Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL!! >> 10/15/2014 1.3950 SELL << 10/17/2014 sp run to 3,45. Great signal
AJAC 16.67%
AJAC 0.0014 16.67%
AJAC 0.0014 16.67%
Sierra blog is POS
Possible ebola in the Netherlands, the guy is a few days ago returned from holiday in Mecca.
Pres. Obama weighs quarantining health workers returning from W. Africa.
AJAC 0.0014 FALLING
IBIO POWER!!!
AJAC 0.0014 HIT 7.69%
AJAC 0.0014 HIT 7.69%
Ebola fear an epidemic in US, official says http://www.foxnews.com/health/2014/10/24/ebola-fear-epidemic-in-us-official-says/
Who's short #LoL
Ghehe shorty #Burn
Mapp Biopharmaceuticals’ experimental Ebola drug ZMapp is perhaps the most advanced drug to date, and is also on the WHO’s list for the trial candidates. However, supplies of the drug have been exhausted. The company is currently looking for different ways to increase production, one of which is collaboration with Caliber Biotherapeutics and Ibio Inc (IBIO)
http://www.bidnessetc.com/27717-tekmira-gains-on-new-ebola-drug-update/2/
Buying 1,44 :)
AJAC LOAD THE DIP, MJ PLAY
AJAC LOAD THE DIP, MJ PLAY
it's noth done, strongbuy now!
Loaded 1,57
#Ebola-Verdachtsfall Oberhausen, Patient ist Schwarzafrikaner, er war bis vor kurzem in Ghana, klagt jetzt über hohes Fieber und Erbrechen!
#Ebola-Verdachtsfall Oberhausen, Patient ist Schwarzafrikaner, er war bis vor kurzem in Ghana, klagt jetzt über hohes Fieber und Erbrechen!
— Frank Schneider (@chefreporterNRW) October 23, 2014
IBIO *********Must Read Due Diligence**********
iBio Expands Exclusive Product Collaboration With Novici Biotech
"iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products"
http://money.cnn.com/news/newsfeeds/articles/marketwire/1153221.htm
Novici is working with Mapp:
U.S. Will Increase Production of the Ebola Drug ZMapp, but May Not Meet Demand
"Mapp is said to be working with another small company, Novici Biotech, which has a method of tweaking the genetic instructions for the antibodies in a way that could boost production."
http://www.nytimes.com/2014/10/02/world/us-to-increase-production-of-experimental-drug-but-may-not-meet-demand.html?_r=0
iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak
Marketwired iBio, Inc. Oct 16, 2014 8:31 AM
NEWARK, DE--(Marketwired - Oct 16, 2014) - iBio, Inc. (NYSE MKT: IBIO) today confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunchâ„¢ platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.
Based on published scientific data, the superior homogeneity of antibody glysolylation (the addition of sugars to proteins) in plants can provide significant efficacy advantages over similar antibodies produced in Chinese hamster ovary (CHO) cells.
iBio has offered to assist the U.S. government by making its proprietary technology available for emergency use to enable the manufacture and yield optimization of certain experimental antibody-based drugs that address the current Ebola virus outbreak, to the extent such assistance is requested by the government.
IBIO only play on ZMapp for Ebola
The producer of the preferred Ebola drug ZMapp is Mapp Biopharmaceuticals, a private company. The United States Health and Human Services Department has a $42 million dollar contract with Mapp to advance the commercial production of ZMapp
Mapp Bio currently is unable to produce large quantities of this drug and needs third parties to assist in production. The most likely candidate to do that is Caliber Biotherapeutics. Caliber has a huge facility for producing vaccines; but Caliber is also a private company and that's where iBio comes in:
iBio licenses it's iBioLaunchâ„¢ platform to Caliber, and therefore iBio's technology will be crucial to speeding up the production of ZMapp to deal with the exploding Ebola epidemic.
iBioLaunchâ„¢ uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems:
Ability to synthesize complex proteins at which other systems have failed
Simplicity, scalability and flexibility
Reduced capital investment
Lower operating costs
Surge capacity
Rapid production times – gene sequence to factory-scale protein harvest
Eliminates the need of bioreactors
Low risk of contamination by animal pathogens
Based on available research, I believe that the most likely scenario going forward is that Mapp will produce ZMapp using both a traditional mammalian process and continue with the plant based process that they already use. However, the facility that Mapp is currently using can only produce 10-20 doses by year end. Caliber's facilities (using Ibio's proprietary technology) can produce thousands of doses in a shorter time frame to treat the thousands of people who currently are or will be suffering from Ebola in Africa and beyond.
For more info please read the articles below:
http://www.hhs.gov/news/press/2014pres/09/20140902b.html
http://www.smallcapnetwork.com/Ibio-About-To-Help-Mass-Produce-Ebola-Drug-ZMapp/s/via/24698/article/view/p/mid/1/id/3/
http://seekingalpha.com/news/2026025-ibio-jumps-on-possible-zmapp-production-ramp
http://seekingalpha.com/article/2578145-ibios-role-in-ebola-response-illustrates-the-companys-strength?uprof=44
*All opinions stated are solely my own and are no substitute for your own research. Happy Investing!
IBIO *********Must Read Due Diligence**********
iBio Expands Exclusive Product Collaboration With Novici Biotech
"iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products"
http://money.cnn.com/news/newsfeeds/articles/marketwire/1153221.htm
Novici is working with Mapp:
U.S. Will Increase Production of the Ebola Drug ZMapp, but May Not Meet Demand
"Mapp is said to be working with another small company, Novici Biotech, which has a method of tweaking the genetic instructions for the antibodies in a way that could boost production."
http://www.nytimes.com/2014/10/02/world/us-to-increase-production-of-experimental-drug-but-may-not-meet-demand.html?_r=0
iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak
Marketwired iBio, Inc. Oct 16, 2014 8:31 AM
NEWARK, DE--(Marketwired - Oct 16, 2014) - iBio, Inc. (NYSE MKT: IBIO) today confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunchâ„¢ platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.
Based on published scientific data, the superior homogeneity of antibody glysolylation (the addition of sugars to proteins) in plants can provide significant efficacy advantages over similar antibodies produced in Chinese hamster ovary (CHO) cells.
iBio has offered to assist the U.S. government by making its proprietary technology available for emergency use to enable the manufacture and yield optimization of certain experimental antibody-based drugs that address the current Ebola virus outbreak, to the extent such assistance is requested by the government.
IBIO only play on ZMapp for Ebola
The producer of the preferred Ebola drug ZMapp is Mapp Biopharmaceuticals, a private company. The United States Health and Human Services Department has a $42 million dollar contract with Mapp to advance the commercial production of ZMapp
Mapp Bio currently is unable to produce large quantities of this drug and needs third parties to assist in production. The most likely candidate to do that is Caliber Biotherapeutics. Caliber has a huge facility for producing vaccines; but Caliber is also a private company and that's where iBio comes in:
iBio licenses it's iBioLaunchâ„¢ platform to Caliber, and therefore iBio's technology will be crucial to speeding up the production of ZMapp to deal with the exploding Ebola epidemic.
iBioLaunchâ„¢ uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems:
Ability to synthesize complex proteins at which other systems have failed
Simplicity, scalability and flexibility
Reduced capital investment
Lower operating costs
Surge capacity
Rapid production times – gene sequence to factory-scale protein harvest
Eliminates the need of bioreactors
Low risk of contamination by animal pathogens
Based on available research, I believe that the most likely scenario going forward is that Mapp will produce ZMapp using both a traditional mammalian process and continue with the plant based process that they already use. However, the facility that Mapp is currently using can only produce 10-20 doses by year end. Caliber's facilities (using Ibio's proprietary technology) can produce thousands of doses in a shorter time frame to treat the thousands of people who currently are or will be suffering from Ebola in Africa and beyond.
For more info please read the articles below:
http://www.hhs.gov/news/press/2014pres/09/20140902b.html
http://www.smallcapnetwork.com/Ibio-About-To-Help-Mass-Produce-Ebola-Drug-ZMapp/s/via/24698/article/view/p/mid/1/id/3/
http://seekingalpha.com/news/2026025-ibio-jumps-on-possible-zmapp-production-ramp
http://seekingalpha.com/article/2578145-ibios-role-in-ebola-response-illustrates-the-companys-strength?uprof=44
*All opinions stated are solely my own and are no substitute for your own research. Happy Investing!
IBIO on the WHO’s list for the trial candidates(EBOLA)>
Mapp Biopharmaceuticals’ experimental Ebola drug ZMapp is perhaps the most advanced drug to date, and is also on the WHO’s list for the trial candidates. However, supplies of the drug have been exhausted. The company is currently looking for different ways to increase production, one of which is collaboration with Caliber Biotherapeutics and Ibio Inc (IBIO)
http://www.bidnessetc.com/27717-tekmira-gains-on-new-ebola-drug-update/2/
IBIO on the WHO’s list for the trial candidates(EBOLA)>
Mapp Biopharmaceuticals’ experimental Ebola drug ZMapp is perhaps the most advanced drug to date, and is also on the WHO’s list for the trial candidates. However, supplies of the drug have been exhausted. The company is currently looking for different ways to increase production, one of which is collaboration with Caliber Biotherapeutics and Ibio Inc (IBIO)
http://www.bidnessetc.com/27717-tekmira-gains-on-new-ebola-drug-update/2/
@MajorNews911 #BREAKING: Amber Vinson is #Ebola FREE. @RayVilleda reports
https://twitter.com/MajorNews911/status/525044038987444225
IBIO NEWS!!!!! IBio Expands Exclusive Product Collaboration With Novici Biotech
Quote:NEWARK, DE, Oct 22, 2014 (Marketwired via COMTEX) -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.
In April 2013, iBio announced the achievement of a technology transfer milestone when Novici was able to use the iBioLaunch system in a challenge study, without any involvement of iBio, to reliably replicate production of commercial yields of targeted biotherapeutics and vaccines. An additional benchmark was achieved in a second live-fire study in May 2013 when Novici used iBioLaunch technology to produce a recombinant vaccine candidate for H7N9 influenza within 21 days of receiving initial antigen sequence information from iBio. Subsequently, the two companies have worked together on iBio-proprietary and third party antibody product candidates addressing both chronic therapy and acute infectious disease treatment.
Novici has previously applied GRAMMR technology successfully for gene and protein optimization to rapidly increase the expression yields of certain target products without alteration of the structure and function of the proteins themselves. By increasing the efficiency with which a desired product can be manufactured, without changing the characteristic of the product or established downstream purification processes, manufacturing capacity of existing facilities can be increased when needed to address pandemic or bioterrorism threats or other urgent needs without the costs and time required to enlarge existing or build additional facilities.
IBIO NEWS!!!!! IBio Expands Exclusive Product Collaboration With Novici Biotech
Quote:NEWARK, DE, Oct 22, 2014 (Marketwired via COMTEX) -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.
In April 2013, iBio announced the achievement of a technology transfer milestone when Novici was able to use the iBioLaunch system in a challenge study, without any involvement of iBio, to reliably replicate production of commercial yields of targeted biotherapeutics and vaccines. An additional benchmark was achieved in a second live-fire study in May 2013 when Novici used iBioLaunch technology to produce a recombinant vaccine candidate for H7N9 influenza within 21 days of receiving initial antigen sequence information from iBio. Subsequently, the two companies have worked together on iBio-proprietary and third party antibody product candidates addressing both chronic therapy and acute infectious disease treatment.
Novici has previously applied GRAMMR technology successfully for gene and protein optimization to rapidly increase the expression yields of certain target products without alteration of the structure and function of the proteins themselves. By increasing the efficiency with which a desired product can be manufactured, without changing the characteristic of the product or established downstream purification processes, manufacturing capacity of existing facilities can be increased when needed to address pandemic or bioterrorism threats or other urgent needs without the costs and time required to enlarge existing or build additional facilities.
AJAC MJ NEWS 0.0017 21.43%
AJAC MJ NEWS 0.0017 21.43%
$4++ TODAY
IBIO POWERRRRRRR!!!!
Yeahh gonzilee in the house, big up next week :)
IBIOOOOO WEEEEEEEEE
IBIO WOW!!! 2.72 GOING CRAZY